For example, around 50% of IBD patients treated with the current standard of care, Infliximab (an anti-TNFα) or Vedolizumab (an anti-α4β7 integrin) do not respond satisfactorily to therapy [15,16]. This evidence concerns the gene TNF and inflammatory bowel disease.